Your session is about to expire
← Back to Search
Daratumumab for Heart Transplant Waitlist Patients
Study Summary
This trial is testing whether a drug that eliminates antibody-producing plasma cells can lower the level of preformed antibodies in patients awaiting heart transplantation. If successful, this could decrease transplant waitlist time and reduce mortality.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had an allergic reaction or intolerance to daratumumab or Daratumumab-SC in the past.You have a medical condition that prevents you from taking medication to prevent herpes zoster (shingles).You have had moderate or severe asthma that has lasted for a long time in the past two years, or your asthma is not well controlled.
- Group 1: Daratumumab-SC Injection
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any opportunities for volunteers to join this clinical investigation?
"Affirmative, the details available on clinicaltrials.gov reveal that this medical trial is currently recruiting patients. It was initially uploaded to the website on July 1st 2021 and last modified on September 20th 2021. The goal is to enroll 12 individuals from a single location."
Is Daratumumab-SC an efficacious and innocuous treatment option?
"The safety of Daratumumab-SC is estimated to be a 1 due to the preliminary nature of this Phase 1 clinical trial, meaning there has not been adequate data collection on efficacy or safety."
Has Daratumumab-SC been applied in any other medical experiments?
"Currently, 140 studies exploring Daratumumab-SC are in operation. Of these active trials, 26 have reached Phase 3 of the research process. While much of this trial data is originating from Harrison, New york, an extensive total of 5564 medical centres around the world are taking part in such experiments."
What is the scale of the participants in this trial?
"Affirmative. Clinicaltrials.gov's information demonstrates that this medical experiment, initially announced on July 1st 2021, is currently recruiting patients. 12 subjects must be recruited from a single site for the trial to take place successfully."
What maladies has Daratumumab-SC been demonstrated to remediate?
"Daratumumab-SC is a highly efficacious treatment for biological response modifiers, and can also be used to alleviate refractory multiple myeloma, relapse or refractory multiple myeloma, as well as cell transplant related issues."
Is the age limit for this medical trial set at fifty-five or older?
"Patients who are 18 years or older, but younger than 75 can apply to take part in this medical trial."
Which demographics are eligible to participate in this clinical experiment?
"Criteria for enrolment involves both age restrictions (18-75) and an allosensitization diagnosis. As of now, a dozen candidates have been admitted into the trial."
Share this study with friends
Copy Link
Messenger